Experimental Anti-Cancer Synthetic Molecule Targets Tumor Cell Growth and Angiogenesis, Centre National de la Recherche Scientifique Study

Published: Jun 20, 2008

ScienceDaily — A recent study conducted by three French CNRS (Centre National de la Recherche Scientifique) laboratories describes a new candidate anti-cancer drug, named HB-19. In contrast to conventional anti-cancer drugs, HB-19 has a dual mechanism of action by its capacity to target independently both tumor cell growth, as well as tumor angiogenesis (formation of new blood vessels which bring necessary nutrients and oxygen to the tumor mass).

Back to news